A Brain Tumor is the growth of abnormal cells in the tissues of the brain. Brain tumors can be benign (not cancer) or malignant (cancer).
Patients diagnosed with a type of brain tumor survived for longer when they were treated aggressively with surgery, radiation and chemotherapy.
For decades, a small group of cutting-edge medical researchers have been studying a biochemical, DNA tagging system, which switches genes on or off. Many have studied it in bacteria and now some have seen signs of it in, plants, flies, and even human brain tumors.
Analysis of the entire tumor RNA picks up more clinically relevant genetic changes in children with cancer than traditional diagnostic methods, new research has shown.
INTEGRA Biosciences is proud to be supporting vital translational research into diffuse intrinsic ponsglioma (DIPG) – a rare childhood brain tumor – at the Ludwig Maximilian University of Munich (LMU) with a festive donation of 20,000 EUR.
Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.
Unlocking the genetic mysteries behind pediatric brain tumors is at the heart of the mission of the Center for Data Driven Discovery in Biomedicine (D3b) at Children's Hospital of Philadelphia.
Researchers demonstrated that cell-free DNA from CSF could be employed to examine MRD in children treated for the brain tumor medulloblastoma.
Scientists have discovered a new link that could bring the scientific and medical community closer to understanding why glioblastoma, the most common malignant brain tumor, is deadlier in males than females.
Multi-institutional researchers have succeeded in efficiently delivering an immune checkpoint inhibitor (ICI) into the mouse brain, confirming its high efficacy and specificity in treating orthotopically transplanted mice with glioblastoma (GBM). The research was published in Nature Biomedical Engineering.
A surprising discovery may offer a promising new direction in the study of multiple sclerosis and other diseases of hypomyelination – when axons of neurons are not covered sufficiently in fatty sheaths (myelin), which disrupts communication between nerve cells.
The changes that occur in individual cancer cells in due course detail the varied development of brain tumors.
A new study coordinated by the University of Trento could have identified the cell of origin of medulloblastoma—a malignant tumor in children that affects the central nervous system. In this study, scientists have used organoids to replicate the tumor tissue, for the first time.
Preclinical research from The University of Texas MD Anderson Cancer Center finds that although glioblastoma stem cells (GSCs) can be targeted by natural killer (NK) cells, they are able to evade immune attack by releasing the TFG-β signaling protein, which blocks NK cell activity.
Medulloblastoma is a rare but devastating childhood brain cancer. This cancer can spread through the spinal fluid and be deposited elsewhere in the brain or spine.
Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.
In far too many cases over the years, scientists have discovered promising new cancer treatments, only to report later that the tumor cells found ways to become resistant. These disappointing results have made overcoming drug resistance a major goal in cancer research.
For many cancers, doctors are increasingly looking to the DNA that solid tumors shed into the blood stream to help with diagnosis and monitoring.
If cancer is a series of puzzles, a new study pieces together how several of those puzzles connect to form a bigger picture.
The metabolic enzyme IL4I1 (Interleukin-4-Induced-1) promotes the spread of tumor cells and suppresses the immune system.
New insight into a gene that controls energy production in cancer stem cells could help in the search for a more effective treatment for glioblastoma.